{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:20:50Z","timestamp":1795188050086,"version":"4.10.3"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Olanzapine and risperidone have emerged as the most widely used drugs as short-term prescription in the treatment of behavioral disturbances in dementia. The present systematic review and meta-analysis was hence performed to investigate the effectiveness and safety profile of olanzapine and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD), aiming to provide updated suggestion for clinical physicians and caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective controlled clinical studies were included, of which available data was extracted. Outcomes of BEHAVE-AD scores with the variation of grades, specific behaviors variables, as well as safety signals were pooled for the analysis by odds rates and weighted mean differences, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>Medline, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and WanFang.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria:<\/jats:title>\n                    <jats:p>Prospective, controlled clinical studies, conducted to compare the effectiveness and safety profile of olanzapine and risperidone in the treatment of BPSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis:<\/jats:title>\n                    <jats:p>Interested data including baseline characteristics and necessary outcomes from the included studies were extracted independently by 2 investigators. BEHAVE-AD scale was adopted to assess the efficacy in the present study. All behaviors were evaluated at the time of the initiation of the treatment, as well as the completion of drugs courses. Adverse events were assessed with the criteria of Treatment Emergent Symptom Scale, or Coding Symbols for a Thesaurus of Adverse Reaction Terms dictionary. Weighted mean difference was used for the pooled analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 2427 participants were included in the present meta-analysis. Comparative OR on response rate, and remarkable response rate between olanzapine and risperidone was 0.65 (95% CI: 0.51\u20130.84;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0008), and 0.62 (95% CI: 0.50\u20130.78;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001), respectively. There were statistical differences observed by olanzapine on the improvement of variables including delusions (WMD, \u22121.83, 95% CI, \u22123.20, \u22120.47), and nighttime behavior disturbances (WMD, \u22121.99, 95% CI, \u22123.60, \u22120.38) when compared to risperidone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results suggested that olanzapine might be statistically superior to risperidone on the reduction of BPSD of Alzheimer\u2019s disease, especially in the relief of delusions and nighttime behavior disturbances. In addition, olanzapine was shown statistically lower risks of agitation, sleep disturbance, and extrapyramidal signs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000035663","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:02:54Z","timestamp":1720195374000},"page":"e35663","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer\u2019s disease: Systematic review and meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7890-7663","authenticated-orcid":false,"given":"Zhihua","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Geriatric Psychiatry, Quzhou Third Hospital, Quzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Quzhou Third Hospital, Quzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0920-6083","authenticated-orcid":false,"given":"Lingyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Quzhou Third Hospital, Quzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s12325-022-02075-8","article-title":"Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a network meta-analysis.","volume":"39","author":"Yunusa","year":"2022","journal-title":"Adv Ther"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"e2215678","DOI":"10.1001\/jamanetworkopen.2022.15678","article-title":"Medication fill patterns for cognitive and behavioral or psychological symptoms of Alzheimer disease and related dementias.","volume":"5","author":"Bangerter","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2021.4417","article-title":"Research criteria for the behavioral variant of Alzheimer disease: a systematic review and meta-analysis.","volume":"79","author":"Ossenkoppele","year":"2022","journal-title":"JAMA Neurol"},{"key":"R4-20260109","first-page":"S39","article-title":"Managing the burden of dementia related delusions and hallucinations.","volume":"69","author":"Small","year":"2020","journal-title":"J Fam Pract"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/YIC.0000000000000358","article-title":"Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer\u2019s disease: a systematic review.","volume":"36","author":"Vinasi","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1533317510390351","article-title":"Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence.","volume":"26","author":"Mittal","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2147\/NDT.S91917","article-title":"Lack of tolerable treatment options for patients with schizophrenia.","volume":"11","author":"Citrome","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0000000000000221","article-title":"Antipsychotic drug exposure and risk of fracture: a systematic review and meta-analysis of observational studies.","volume":"33","author":"Papola","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.","volume":"13","author":"Deberdt","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1192\/bjp.bp.111.107631","article-title":"Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services.","volume":"201","author":"Barnes","year":"2012","journal-title":"Br J Psychiatry"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease.","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-20260109","doi-asserted-by":"crossref","DOI":"10.1592\/phco.22.1.1.33496","article-title":"Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.","volume":"22","author":"Ellingrod","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R13-20260109","first-page":"68","article-title":"Comparative effects of olanzapine and risperidone in Alzheimer patients associated with psychiatric symptom.","volume":"12","author":"Zunong","year":"2019","journal-title":"Chin J Clin Ration Drug Use"},{"key":"R14-20260109","first-page":"154","article-title":"Comparison of olanzapine and risperidone in Alzheimer patients associated with psychiatric symptom.","volume":"35","author":"Kou","year":"2021","journal-title":"Contin Med Educ"},{"key":"R15-20260109","first-page":"13","article-title":"Comparison efficacy of risperidone oral solution and olanzapine in the treatment of elderly dementia behavioral and psychological symptoms.","volume":"9","author":"Qu","year":"2016","journal-title":"Chin J Clin Ration Drug Use"},{"key":"R16-20260109","first-page":"102","article-title":"The comparative study of olanzapine and risperidone in the treatment of dementia patients with behavioral and psychological symptoms.","volume":"9","author":"Huang","year":"2012","journal-title":"China Med Herald"},{"key":"R17-20260109","first-page":"145","article-title":"Effect comparison of olanzapine and risperidone treating patients with Alzheimer disease associated with psychiatric symptom.","volume":"22","author":"Zhong","year":"2015","journal-title":"China Mod Med"},{"key":"R18-20260109","first-page":"97","article-title":"Clinical comparative analysis of olanzapine and risperidone in the treatment of mental and behavioral symptoms of senile dementia.","volume":"14","author":"Wang","year":"2019","journal-title":"China Prac Med"},{"key":"R19-20260109","first-page":"69\u2009+\u200971","article-title":"Effect of olanzapine and risperidone in the treatment of behavioral and psychological symptoms of senile dementia.","volume":"34","author":"Lin","year":"2018","journal-title":"Chin Community Doctors"},{"key":"R20-20260109","first-page":"1772","article-title":"Clinical comparison of olanzapine and risperidone in patients with Alzheimer disease associated with psychiatric symptom.","volume":"31","author":"Cai","year":"2011","journal-title":"Chin J Gerontol"},{"key":"R21-20260109","first-page":"665","article-title":"Comparison of curative effect and safety of olanzapine and risperidone in the treatment of senile dementia combined with mental disorders.","volume":"24","author":"Li","year":"2017","journal-title":"Clin Med Eng"},{"key":"R22-20260109","first-page":"10","article-title":"Effects of olanzapine and risperidone on behavioral and psychological disorders associated with senile dementia.","volume":"3","author":"Li","year":"2018","journal-title":"Clin Res Pract"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"659538","DOI":"10.3389\/fonc.2021.659538","article-title":"Individualized nomogram for predicting survival in patients with brain metastases after stereotactic radiosurgery utilizing driver gene mutations and volumetric surrogates.","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20260109","first-page":"147","article-title":"Comparative study of olanzapine and risperidone in dementia patients with behavioral and psychological symptoms.","volume":"11","author":"He","year":"2013","journal-title":"Guide China Med"},{"key":"R25-20260109","first-page":"232","article-title":"Efficacy of olanzapine and risperidone in behavioral and psychological disorders with senile dementia.","author":"Tang","year":"2019","journal-title":"Health Everyone"},{"key":"R26-20260109","first-page":"1633","article-title":"Comparison between the clinical effects of olanzapine and risperidone in treatment of Alzheimer patients with behavioral and psychological symptoms.","volume":"19","author":"Luo","year":"2013","journal-title":"Hebei Med"},{"key":"R27-20260109","first-page":"2036","article-title":"Clinical effects of olanzapine in treatment of elder Alzheimer patients with behavioral and psychological symptoms.","volume":"26","author":"Xiong","year":"2017","journal-title":"Henan Med Res"},{"key":"R28-20260109","first-page":"4207","article-title":"Study the treatment of mental behavior with senile dementia disorders with olanzapine.","volume":"35","author":"Li","year":"2014","journal-title":"Jilin Med"},{"key":"R29-20260109","first-page":"41","article-title":"Analysis of clinical efficacy of olanzapine in treatment of mental behavior with senile dementia disorders.","volume":"42","author":"Wei","year":"2015","journal-title":"J Int Psychiatry"},{"key":"R30-20260109","first-page":"679","article-title":"Effectiveness and safety assessment of olanzapine and risperidone in Alzheimer patients associated with psychiatric symptom.","volume":"29","author":"Jiang","year":"2015","journal-title":"Pract Geriatr"},{"key":"R31-20260109","first-page":"188","article-title":"Comparison of olanzapine and risperidone in elder patients with Alzheimer disease associated with psychiatric symptom.","volume":"28","author":"Tian","year":"2016","journal-title":"Strait Pharm J"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1440-1819.2007.01729.x","article-title":"Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer\u2019s disease: preliminary findings from a naturalistic, retrospective study.","volume":"61","author":"Rocca","year":"2007","journal-title":"Psychiatry Clin Neurosci"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4088\/JCP.v64n0617","article-title":"A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.","volume":"64","author":"Fontaine","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gps.490","article-title":"The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer\u2019s disease patients.","volume":"17","author":"Beeri","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1212\/01.WNL.0000036904.73393.E4","article-title":"The incremental direct costs associated with behavioral symptoms in AD.","volume":"59","author":"Murman","year":"2002","journal-title":"Neurology"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12325-021-01964-8","article-title":"The efficacy of high- or low-frequency transcranial magnetic stimulation in Alzheimer\u2019s disease patients with behavioral and psychological symptoms of dementia.","volume":"39","author":"Jiang","year":"2022","journal-title":"Adv Ther"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-215061","article-title":"A comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD sub-syndromes in early-onset and late-onset Alzheimer\u2019s disease.","volume":"85","author":"Altomari","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ppc.13069","article-title":"The effect of Alzheimer\u2019s blanket activity program on behavioral symptoms, activities of daily living, and quality of life.","volume":"58","author":"Yildiz","year":"2022","journal-title":"Perspect Psychiatr Care"},{"key":"R39-20260109","first-page":"S1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"R40-20260109","first-page":"2053","article-title":"A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer\u2019s disease.","volume":"34","author":"Zhu","year":"2021","journal-title":"Pak J Pharm Sci"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/136515001317021644","article-title":"The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety.","volume":"5","author":"Peuskens Marc De Hert Michael Jones","year":"2001","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13651500510014783","article-title":"A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials.","volume":"9","author":"Mudge","year":"2005","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm.","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat Rev Neurosci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:03:32Z","timestamp":1767967412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":44,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035663","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}